Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib
IASLC WCLC 2025
Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) who experienced disease progression after previous treatment with a TKI (Abstract PL02.15).
The ASCO Post Staff
Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor-suppressor gene mutations.
The ASCO Post Staff
Patrick Goodley, MBBChir, MRCP, of Manchester University NHS Foundation Trust, reports results from a study that looked at treatment and survival rates in people aged 75 to 80 years diagnosed with screen-detected lung cancer in two targeted lung cancer screening implementation settings (Abstract PL03.19).
The ASCO Post Staff
Gerrina Ruiter, MD, PhD, of the Netherlands Cancer Institute, discusses data from the Beamion LUNG-1 trial, which is evaluating zongertinib—an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing EGFR—in patients with HER2-mutant advanced or metastatic non–small cell lung cancer (NSCLC). This analysis of the trial focused on previously treated patients with active brain metastases (cohort 4) or stable/asymptomatic brain metastases (cohort 1) at baseline (Abstract PT2.12.03).
The ASCO Post Staff
Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable non–small cell lung cancer (NSCLC), regardless of nodal status (Abstract MA04.05).
The ASCO Post Staff
Kelly G. Paulson, MD, PhD, of Providence Swedish Cancer Institute (Seattle, WA) and lead of the Center for Immuno-Oncology at Paul G. Allen Research Center, reviews findings from the safety and efficacy data from the phase Ib DeLLphi-303 trial. The study examined tarlatamab, a bispecific T-cell engager, in combination with PD-L1 inhibition as first-line maintenance; the regimen led to unprecedented overall survival results in this patient population, and had an acceptable safety profile (Abstract OA13.01).
For more information on DeLLphi-303, read more in The Lancet Oncology.
